SCHEMBL22434744

SCHEMBL22434744

Cc1ccc(Cl)c2c1cc(C)n2C

nearest known ligand 0.34

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.34
ALDH1A1 P00352 2/20 0.33
APOBEC3G Q9HC16 1/20 0.33
HSD11B1 P28845 3/20 0.32
KDM4E B2RXH2 2/20 0.32
MAPT P10636 2/20 0.32
CYP1A2 P05177 1/20 0.32
BRD1 O95696 1/20 0.32
TAF1 P21675 1/20 0.32
BRPF1 P55201 1/20 0.32
CASP1 P29466 1/20 0.32
CASP7 P55210 1/20 0.32
HSD17B10 Q99714 1/20 0.32
SIRT2 Q8IXJ6 1/20 0.31
PRMT5 O14744 1/20 0.31
PSMB8 P28062 1/20 0.31
HPGD P15428 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22434746 0.89 KDM4E (0.34) ALDH1A1HSD11B1KDM4EMAPTCYP1A2
SCHEMBL22434747 0.82 HSD11B1 (0.36) HSD11B1MAPT
SCHEMBL22434751 0.82 ALKBH5 (0.42) CYP3A4ALDH1A1KDM4EMAPTCYP1A2
SCHEMBL22434677 0.80 CYP19A1 (0.40) ALDH1A1KDM4EMAPTCYP1A2HSD17B10
SCHEMBL22434864 0.75 PARP15 (0.33) KDM4EMAPTCYP1A2CASP1CASP7
SCHEMBL22434866 0.75 HSD11B1 (0.36) ALDH1A1HSD11B1KDM4EMAPTBRD1
SCHEMBL20504882 0.74 ALDH1A1 (0.37) CYP3A4ALDH1A1MAPTHPGD
SCHEMBL22434876 0.73 SIRT2 (0.37) HSD11B1KDM4EMAPTCYP1A2SIRT2
SCHEMBL22434877 0.72 HSD11B1 (0.30) HSD11B1
SCHEMBL14043783 0.71 HSD11B1 (0.34) CYP3A4ALDH1A1APOBEC3GHSD11B1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11241431-B2 N-substituted indole derivatives as PGE2 receptor modulators IDORSIA PHARMACEUTICALS LTD (CH) 2022-02-08 US disclosed
US-20200289507-A1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2020-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200289507-A1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS PTGER1, PTGER4, PTGER2 CYP3A4 154/4885ALDH1A1 761/4885APOBEC3G 4296/4885
US-11241431-B2 N-substituted indole derivatives as PGE2 receptor modulators PTGER1, PTGER4, PTGER2 CYP3A4 154/4885ALDH1A1 761/4885APOBEC3G 4296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.